Mindmed announces transitions to management team

- bradford cross, chief technology officer to transition; don gehlert, phd, chief scientific officer to transition to senior scientific advisor - new york, dec. 29, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading biotech company developing psychedelic-inspired therapies, today announced that its chief technology officer, bradford cross, has transitioned from his role. "on behalf of the board of directors and executive team, i would like to thank bradford for his contributions to the company and wish him all the best in his future endeavors," said robert barrow, chief executive officer and director of mindmed.
MNMD Ratings Summary
MNMD Quant Ranking